|Slideshows|October 2, 2020

Best Practices for Motivational Pharmacotherapy Sessions

Author(s)Roberto Lewis-Fernández, MD, Angela A. Coombs, MD

These techniques may help promote self-efficacy and elicit patients’ commitment to resolve ambivalence about treatment.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Polypharmacy in Clozapine-Treated Patients: A Retrospective Analysis

ByBrian Miller, MD, PhD, MPH

November 17th 2025

FDA Clears Deep Transcranial Magnetic Stimulation for Adolescents With MDD

ByLeah Kuntz

November 14th 2025

iclepertin cognitive impairment schizophrenia

Iclepertin Found Ineffective in Treating Cognitive Impairment Associated With Schizophrenia

ByJessica Walters

November 13th 2025

Everything You Need to Know About the Approval of Lumateperone for Major Depressive Disorder

ByLeah Kuntz

November 13th 2025

Placebo Response Rates Vary Across Psychiatric Disorders

ByMasha Impallaria, MD,Ahmed Sakr, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

November 12th 2025

Latest CME

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Register now!

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Best Practices for Motivational Pharmacotherapy Sessions

Newsletter

Related Content

Polypharmacy in Clozapine-Treated Patients: A Retrospective Analysis

FDA Clears Deep Transcranial Magnetic Stimulation for Adolescents With MDD

Iclepertin Found Ineffective in Treating Cognitive Impairment Associated With Schizophrenia

Everything You Need to Know About the Approval of Lumateperone for Major Depressive Disorder

Placebo Response Rates Vary Across Psychiatric Disorders

Latest CME

Southern Florida Psychiatry Conference

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

ADHD: Correcting Careless Myths

Planned FDA Investigational New Drug Application: SPC-15 for the Treatment of PTSD

ADHD and Mild Cognitive Impairment/Early Dementia: A Clinical Reality

Tonmya Available Commercially for Treatment of Fibromyalgia

Making Chatbots Safe For Suicidal Patients